Good pelvic health is an essential element in every human being, but it is of more essence in women. Unfortunately, pelvic disorders such as urinary incontinence are usually not given as much coverage as other ailments, yet they affect over 250 million women across the world. However, with seasoned healthcare investors like Marc Beer in play, change is about to be felt across the entire healthcare realm.
Through his company Renovia Inc., Marc Beer has been spearheading the development of pharmaceutical and biotechnological devices and diagnostics that will aid in the treatment of pelvic disorders. This will help reduce the number of women who have had to deal with problems like urinary incontinence on a daily basis. Learn more: https://patch.com/massachusetts/boston/renovias-marc-beer-raises-42m-treat-womens-health-issues
Renovia Inc.’s, first win
Renovia, under the direction of Marc Beer, and its two other founders, celebrated its first win early this year, after the FDA approved its first product, Leva in April. The product will enable women to deal with the problem of weak pelvic floors after childbirth across the world.
Even more wins
During its series B funding this year, the company was able to raise approximately $32 million in funds and $10 million in venture debt. Marc Beer, the firm’s CEO and chairman announced the success of the funding and expressed his excitement and happiness about the immense support that the investors who took part in series B displayed.
Some of the companies which took part in series B include the Longwood Fund, a healthcare based investment giant which had also participated in the first round of Renovia’s funding. Besides Longwood, Series B financing attracted a plethora of influential investors such as Perceptive advisors, Inova Strategic Investment, Ascension, and Western Technology investment among many others.
According to Marc Beer, the participation of such companies in the financing makes it easy for Renovia to redefine healthcare and help impact the health of the myriads of women who have had to suffer silently with pelvic disorders. He further added that all the investors who participated boast the same vision, as well as the proprietary technology required to create innovative, customized yet affordable treatments for pelvic disorders patients.
The funding will go a long way in enabling Renovia Inc. to develop and test even more products aimed at modernizing pelvic disorder therapy, including a new generation Leva device.
More about Marc Beer
Marc Beer is not a newcomer in the world of healthcare investments. He has been in the industry for more than two decades specializing in the field of biotechnology and pharmaceuticals. This explains why his two-year startup venture, Renovia Inc., has been gaining more leverage with each wake. Before joining hands with Yolanda Lorie and Ramon Iglesias to form Renovia, Beer had been working with a long string of other healthcare companies such as Viacell and Genzyme.